Berberine vs CJC-1295 (without DAC)
Moderate Research vs Well Studied
synergistic Mechanism-based · 51% Berberine helps counteract the insulin-disrupting effects of CJC-1295 (without DAC). A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
Berberine CJC-1295 (without DAC)
Weight 336.36 Da 3,367.97 Da
Half-life ~4 hours 30 minutes - 2 hours
Chain — 30 amino acids
Type Isoquinoline alkaloid (C20H18NO4+) GHRH analog
Key Benefits
Berberine
01 Activation of AMPK, improving cellular energy metabolism and glucose utilization
02 Clinically demonstrated reductions in fasting blood glucose and HbA1c comparable to metformin in some trials
03 Improved lipid profiles with reductions in total cholesterol, LDL cholesterol, and triglycerides
04 Enhanced insulin sensitivity through upregulation of insulin receptor expression
05 PCSK9 inhibition leading to improved LDL cholesterol clearance
06 Gut microbiome modulation favoring beneficial short-chain fatty acid-producing bacteria
07 Anti-inflammatory effects via NF-kB pathway suppression
08 Available over the counter as a dietary supplement without prescription
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Dosing Protocols
Berberine
500 mg 2-3x/day / 2-3x daily with meals
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Side Effects
Berberine
Gastrointestinal distress (diarrhea, cramping, bloating, nausea, flatulence) - most frequent complaint, affecting 10-15% of users, especially at higher doses or without food
Constipation (less common than diarrhea but reported by some users)
Decreased appetite
Mild abdominal discomfort, particularly during the first 1-2 weeks of use
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Contraindications
Pregnancy and breastfeeding (berberine may stimulate uterine contractions and crosses into breast milk)
Neonates and young children (risk of kernicterus - berberine can displace bilirubin from albumin)
Severe hepatic impairment
Concurrent use with medications that have narrow therapeutic indices metabolized by CYP3A4 (e.g., cyclosporine, tacrolimus) without close medical supervision
Known hypersensitivity to berberine or berberine-containing plants
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Research Evidence
Berberine CJC-1295 (without DAC)
Status Moderate Research Well Studied
References 5 studies 5 studies
Latest 2023 November 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.